JNJ Latest Press Releases

-- March 13, 2026 --

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer PRNewswire 12:36 PM

-- March 12, 2026 --

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients Business Wire 8:00 AM

-- March 5, 2026 --

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line PRNewswire 3:55 PM

-- March 3, 2026 --

/C O R R E C T I O N -- Johnson & Johnson/ PRNewswire 7:37 PM

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight PRNewswire 5:31 PM

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) PRNewswire 8:03 AM

-- March 2, 2026 --

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results Business Wire 4:30 PM

-- February 26, 2026 --

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer PRNewswire 2:30 PM

-- February 24, 2026 --

Johnson & Johnson seeks FDA approval of IMAAVY (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) PRNewswire 4:03 PM

-- February 21, 2026 --

TREMFYA (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years PRNewswire 8:00 AM

-- February 19, 2026 --

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer PRNewswire 5:00 PM

-- February 18, 2026 --

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania Business Wire 10:15 AM

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer PRNewswire 7:30 AM

-- February 17, 2026 --

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A Globe Newswire 8:30 AM

FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month PRNewswire 8:00 AM

-- February 13, 2026 --

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial Business Wire 4:18 PM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 9, 2026 --

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference Business Wire 4:16 PM

-- February 6, 2026 --

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium Business Wire 7:00 PM

-- February 2, 2026 --

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference Business Wire 4:34 PM

-- January 27, 2026 --

DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible PRNewswire 3:49 PM

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile Business Wire 8:00 AM

-- January 21, 2026 --

Johnson & Johnson reports Q4 and Full-Year 2025 results Business Wire 6:20 AM

-- January 14, 2026 --

TECVAYLI monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide PRNewswire 4:30 PM

-- January 13, 2026 --

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting PRNewswire 8:00 AM

-- January 10, 2026 --

RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer PRNewswire 10:00 AM

-- January 8, 2026 --

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments Business Wire 8:24 PM

-- January 7, 2026 --

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio Business Wire 2:16 PM

Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration Business Wire 8:00 AM

-- January 6, 2026 --

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study PRNewswire 8:03 AM

-- January 2, 2026 --

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026 Business Wire 8:00 AM

-- December 29, 2025 --

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies Business Wire 8:00 AM

-- December 18, 2025 --

Johnson & Johnson Receives FDA Approval for TRUFILL n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma PRNewswire 8:00 AM

-- December 17, 2025 --

U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE (lazertinib) PRNewswire 6:50 PM

-- December 15, 2025 --

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Business Wire 4:27 PM

-- December 12, 2025 --

U.S. FDA approves AKEEGA as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* PRNewswire 8:26 PM

-- December 9, 2025 --

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma PRNewswire 7:44 AM

-- December 8, 2025 --

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:25 PM

-- December 6, 2025 --

Earlier use of CARVYKTI demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma PRNewswire 9:30 AM

-- December 5, 2025 --

Johnson & Johnson's INLEXZO (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC PRNewswire 4:20 PM

-- December 3, 2025 --

Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 PRNewswire 8:00 AM

-- November 24, 2025 --

Biotech Valuations Rise as New Clinical Platforms Show Progress Globe Newswire 8:30 AM

-- November 17, 2025 --

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy Business Wire 6:07 PM

New long-term data reinforces TREMFYA (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis PRNewswire 8:05 AM

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics Business Wire 8:00 AM

-- November 6, 2025 --

DARZALEX FASPRO is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma PRNewswire 5:08 PM

FDA approval of CAPLYTA (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder PRNewswire 7:30 AM

-- November 5, 2025 --

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference Business Wire 4:50 PM

-- October 29, 2025 --

Johnson & Johnson announces first head-to-head study comparing IMAAVY with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting PRNewswire 8:05 AM

-- October 27, 2025 --

TREMFYA (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years PRNewswire 7:30 AM

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis PRNewswire 7:30 AM

-- October 24, 2025 --

Published in The Lancet: Nipocalimab significantly decreased Sjgren's disease (SjD) activity and severity through substantial reduction in Sjgren's-related autoantibodies PRNewswire 6:32 PM

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis PRNewswire 8:00 AM

-- October 22, 2025 --

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference Business Wire 4:36 PM

-- October 19, 2025 --

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer PRNewswire 10:30 AM

-- October 16, 2025 --

TECVAYLI plus DARZALEX FASPRO combination regimen significantly improves progression-free survival and overall survival versus standard of care PRNewswire 8:02 AM

-- October 14, 2025 --

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025 Business Wire 6:30 AM

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business Business Wire 6:21 AM

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook Business Wire 6:20 AM